CN115884969A - 稠合咪唑类衍生物、其制备方法及其在医药上的应用 - Google Patents

稠合咪唑类衍生物、其制备方法及其在医药上的应用 Download PDF

Info

Publication number
CN115884969A
CN115884969A CN202180050847.9A CN202180050847A CN115884969A CN 115884969 A CN115884969 A CN 115884969A CN 202180050847 A CN202180050847 A CN 202180050847A CN 115884969 A CN115884969 A CN 115884969A
Authority
CN
China
Prior art keywords
formula
compound
groups
mixture
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180050847.9A
Other languages
English (en)
Inventor
杨方龙
张羚
郑亮亮
贺峰
陶维康
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN115884969A publication Critical patent/CN115884969A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

公开了稠合咪唑类衍生物、其制备方法及其在医药上的应用。具体而言，公开涉及一种通式(IM)所示的稠合咪唑类衍生物、其制备方法及含有该衍生物的药物组合物以及其作为治疗剂的用途，特别是作为GLP‑1受体激动剂的用途和用于制备治疗和/或预防糖尿病的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (31)

  1. PCT国内申请，权利要求书已公开。
CN202180050847.9A 2020-09-01 2021-09-01 稠合咪唑类衍生物、其制备方法及其在医药上的应用 Pending CN115884969A (zh)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
CN2020109056934 2020-09-01
CN202010905693 2020-09-01
CN202010984336 2020-09-18
CN2020109843361 2020-09-18
CN2020111240856 2020-10-20
CN202011124085 2020-10-20
CN2020112530771 2020-11-11
CN202011253077 2020-11-11
CN202011407911 2020-12-04
CN2020114079118 2020-12-04
CN202011627733 2020-12-31
CN202011627733X 2020-12-31
PCT/CN2021/115915 WO2022007979A1 (zh) 2020-09-01 2021-09-01 稠合咪唑类衍生物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
CN115884969A true CN115884969A (zh) 2023-03-31

Family

ID=79552285

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180050847.9A Pending CN115884969A (zh) 2020-09-01 2021-09-01 稠合咪唑类衍生物、其制备方法及其在医药上的应用

Country Status (10)

Country Link
US (2) US20230322756A1 (zh)
EP (1) EP4209490A4 (zh)
JP (1) JP2023539584A (zh)
KR (1) KR20230058660A (zh)
CN (1) CN115884969A (zh)
AU (1) AU2021306414A1 (zh)
CA (1) CA3188891A1 (zh)
MX (1) MX2023001980A (zh)
TW (1) TW202220985A (zh)
WO (1) WO2022007979A1 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023537501A (ja) 2020-08-06 2023-09-01 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
JP2023538949A (ja) 2020-08-28 2023-09-12 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
TWI843104B (zh) 2021-05-20 2024-05-21 美商美國禮來大藥廠 類升糖素肽1受體促效劑
KR20240042624A (ko) * 2021-08-04 2024-04-02 상하이 한서 바이오메디컬 컴퍼니 리미티드 시클로알켄계 유도체 조절제, 이의 제조 방법 및 응용
CN116419923B (zh) * 2021-08-24 2024-09-06 东宝紫星(杭州)生物医药有限公司 咪唑并环类化合物及其应用
KR20240073108A (ko) 2021-10-05 2024-05-24 아스트라제네카 아베 Glp-1 수용체 조절제로서의 특정 2,5-디아자바이시클로[4.2.0]옥탄
WO2023057429A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
WO2023057414A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
US12024507B2 (en) 2021-10-25 2024-07-02 Terns Pharmaceuticals, Inc. Compounds as GLP-1R agonists
WO2023111144A1 (en) 2021-12-16 2023-06-22 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
WO2023111145A1 (en) 2021-12-16 2023-06-22 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
WO2023246833A1 (zh) * 2022-06-23 2023-12-28 西藏海思科制药有限公司 一种五并五元环衍生物的药物组合物及其在医药上的应用
WO2024102625A1 (en) 2022-11-11 2024-05-16 Eli Lilly And Company Glucagon-like peptide 1 receptor agonists
WO2024107781A1 (en) 2022-11-16 2024-05-23 Eli Lilly And Company Glucagon-like peptide 1 receptor agonists
WO2024131869A1 (en) * 2022-12-22 2024-06-27 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024160271A1 (zh) * 2023-02-02 2024-08-08 江苏豪森药业集团有限公司 一种环烯类化合物的盐、晶型及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110301161A1 (en) * 2009-12-04 2011-12-08 Boehringer Ingelheim International Gmbh Benzimidazole inhibitors of leukotriene production
US20190382387A1 (en) * 2018-06-13 2019-12-19 Pfizer Inc. GLP-1 Receptor Agonists and Uses Thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099805A1 (en) 2002-05-28 2003-12-04 3-Dimensional Pharmaceuticals, Inc. Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
JP5382952B2 (ja) 2008-03-07 2014-01-08 トランス テック ファーマ，インコーポレイテッド 糖尿病の治療のためのオキサジアゾアントラセン化合物
BRPI1013579A2 (pt) 2009-03-30 2020-11-03 Transtech Pharma, Inc. derivados de azoantraceno substituídos, composições farmacêuticas e métodos de uso dos mesmos
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
KR102466418B1 (ko) 2016-12-16 2022-11-14 화이자 인코포레이티드 Glp-1 수용체 작용제 및 이의 용도
SG11202105241YA (en) * 2018-11-22 2021-06-29 Qilu Regor Therapeutics Inc Glp-1r agonists and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110301161A1 (en) * 2009-12-04 2011-12-08 Boehringer Ingelheim International Gmbh Benzimidazole inhibitors of leukotriene production
US20190382387A1 (en) * 2018-06-13 2019-12-19 Pfizer Inc. GLP-1 Receptor Agonists and Uses Thereof

Also Published As

Publication number Publication date
WO2022007979A1 (zh) 2022-01-13
EP4209490A4 (en) 2023-11-22
KR20230058660A (ko) 2023-05-03
CA3188891A1 (en) 2022-01-13
TW202220985A (zh) 2022-06-01
AU2021306414A1 (en) 2023-05-04
EP4209490A1 (en) 2023-07-12
JP2023539584A (ja) 2023-09-15
US20230322756A1 (en) 2023-10-12
MX2023001980A (es) 2023-02-27
US20240246958A1 (en) 2024-07-25

Similar Documents

Publication Publication Date Title
CN115884969A (zh) 稠合咪唑类衍生物、其制备方法及其在医药上的应用
CN113816948B (zh) 稠合咪唑类衍生物、其制备方法及其在医药上的应用
CN113801136B (zh) 咪唑并杂芳基类衍生物、其制备方法及其在医药上的应用
CN115244056A (zh) 稠合咪唑类衍生物、其制备方法及其在医药上的应用
WO2021254470A1 (zh) 6-氧代-3,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用
CN111107848B (zh) 一种含有酰胺类衍生物的药物组合物及其制备方法和应用
CN114805336A (zh) 稠合咪唑类化合物、其制备方法及其在医药上的应用
CN113874354B (zh) 吡啶酮类衍生物、其制备方法及其在医药上的应用
CN113825757B (zh) 取代的稠合双环类衍生物、其制备方法及其在医药上的应用
KR20240024910A (ko) Glp-1 수용체 작용제 및 이의 조성물과 용도
WO2021244634A1 (zh) 咪唑并吡啶类化合物及其用途
WO2022017365A1 (zh) 含硫异吲哚啉类衍生物、其制备方法及其在医药上的应用
TW202128686A (zh) 稠合雜芳基類衍生物、其製備方法及其在醫藥上的應用
CN114539229A (zh) 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN114149423B (zh) 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用
WO2022268154A1 (zh) 新型抗乙肝化合物
CN115884776A (zh) 杂环大环化合物及其医药用途
WO2023086800A1 (en) Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
CN118496200A (zh) 吲唑啉酮类化合物及其制备方法和用途
CN116640154A (zh) 多环化合物、其制备方法及其在医药上的应用
WO2021121276A1 (zh) 稠合四环类衍生物、其制备方法及其在医药上的应用
CN114456173A (zh) 稠环基取代的环己二酰亚胺类衍生物、其制备方法及其在医药上的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40090843

Country of ref document: HK